Hester Biosciences Ltd Consolidated Net Profit in Q2FY25 up 108% Y-o-Y to Rs. 8.39 crore; Revenue up 19% to Rs. 83.69 crore

▴ Hester Biosciences Ltd
Absolute PAT rose by 38%, aligning with sales growth, and the PAT% increased by 3%, highlighting enhanced operational efficiency.
  • In H1FY25 Net Profit up 48% Y-o-Y to Rs. 15.88 crore
  • In H1FY25 EBITDA up 16% Y-o-Y to Rs. 41.69 crore

Consolidated Financial Highlights

(Rs. Crore)

Particulars

Q2

H1

FY25

FY24

Change %

FY25

FY24

Change %

Divisional Product sales

83.69

69.30

21%

165.96

130.46

27%

Revenue from operations

 

  Includes revenue from

-      Hester Nepal

-      Hester Africa

83.69

 

 

2.13

9.20

70.46

 

 

0.73

1.96

19%

 

 

192%

369%

165.96

 

 

8.45

12.00

158.31

 

 

7.27

3.71

5%

 

 

16%

223%

Gross Profit margin

71%

71%

-

71%

65%

6%

EBITDA

21.96

19.12

15%

41.69

36.00

16%

EBITDA%

26%

27%

-1%

25%

23%

2%

PAT

8.39

4.04

108%

15.88

10.75

48%

PAT%

10%

6%

4%

10%

7%

3%

EPS (In ₹, not annualized)

9.86

4.75

108%

18.66

12.64

48%

 

28 October 2024: Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported consolidated net profit of Rs. 8.39 crore in Q2FY25 ended September 2024 as against a net profit of Rs. 4.04 crore in Q2FY24, growth of 108%. Company reported revenue from operations of Rs. 83.69 crore for Q2FY25, growth of 19% Y-o-Y as compared to revenue from operations of Rs. 70.46 crore in Q2FY24. EBITDA during Q2FY25 ended September 2024 was reported at Rs. 21.96 crore, 15% growth Y-o-Y from Rs. 19.12 crore in Q2FY24. EPS for Q2FY25 was reported at Rs. 9.86 per share. 

 

Company remain focused on diversifying product portfolio by introducing new, innovative solutions across all segments. Alongside this, company continue to enhance our operational efficiency, driving profitability and growth. Company’s goal is to position Hester as a holistic animal health company, meeting the evolving needs of the industry through a comprehensive range of products and services.

 

The subsidiary in Nepal fulfilled export orders from government tenders and met domestic vaccine demand, showcasing its growth potential. Hester Nepal remains debt-free with strong cash flows from the quarter. Hester Africa is actively participating in international tenders and meeting trade demands across various African countries, with increasing awareness and demand for vaccines.

 

H1FY25 Results

Company has reported net profit of Rs. 15.88 crore in H1FY25 ended September 2024 as against net profit of Rs. 10.75 crore in H1FY24, growth of 48%. Company reported revenue from operations of Rs. 165.96 crore for the H1FY25, growth of 5% Y-o-Y. EBITDA during H1FY25 ended September 2024 was reported at Rs. 41.69 crore, 16% growth Y-o-Y from Rs. 36.00 crore in H1FY24. EPS for H1FY25 was reported at Rs. 18.66 per share.

 

Standalone Financial Highlights

 

Revenues                                                                   (₹ Crore)

 

Divisions

Q2

H1

FY25

FY24

Change %

FY25

FY24

Change %

Animal Healthcare

31.67

30.47

4%

63.33

52.94

20%

Poultry Healthcare

40.77

33.96

20%

81.54

64.25

27%

Petcare

1.06

0.94

12%

2.10

1.74

20%

Total Divisional Product Sales

73.50

65.37

12%

146.97

118.93

24%

Others* (one time)

-

-

-

-

26.79

-

Total Sales

73.50

65.37

12%

146.97

145.72

1%

License & services fees

-

1.06

-

-

1.06

-

Revenue from Operations

73.50

66.43

11%

146.97

146.78

0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* includes exports of other pharmaceutical products

 

The divisional product sales has demonstrated growth by 12% and 24% in Q2 and H1 FY25 respectively.

 

 

Animal Healthcare Division

In Q2 FY25, the Animal Healthcare Division maintained its upward trajectory with 4% growth in the quarter and 20% growth in H1, driven by the following factors:

 

Sustained Growth in the Dairy Sector and Product Introductions:

  1. The strong domestic demand for milk and dairy products continued into Q2, further boosting sales within the dairy sector.
  2. The feed supplements, dewormers and anti-infective to support herd health, continued to grow in Q2. The newly launched brand iSumovet MP, a pain relief product, and ProtinC Keto+, a line extension from one of our key brands, showed strong sales trend.

 

Supporting National Immunization Programs:

  1. The Goat Pox vaccine continued to play a crucial role in preventive vaccination against Lumpy Skin Disease in cattle.
  2. Supplies of the PPR vaccine for sheep and goats remained steady as part of the Government of India’s National Immunization Programs.

 

 

Poultry Healthcare Division

In Q2 & H1 FY25, the Poultry Healthcare Division achieved a commendable growth of 20% and 27% respectively:

  1. Vaccine sales grew by 21% in Q2, supported by a significant 59% increase in exports, continuing the strong performance seen in Q1.
  2. To enhance disease control measures in poultry farms, we introduced a new disinfectant, which is also contributing to the growth of our health products segment.

 

Petcare Division

In Q2 FY25, the Petcare Division achieved a growth of 12% and 20% in Q2 & H1 FY25 respectively.

 

During the quarter, Hester launched Diet Fortify, a range of pet food designed to address lifestyle-related health issues in pets. This new product, developed with inputs from veterinarians, strengthens Hester’s market position while offering science-based nutrition to improve pet health.

 

 

Standalone Profitability Analysis

(₹ Crore)

Divisions

Q2

H1

FY25

FY24

Change %

FY25

FY24

Change %

Gross Profit margin

67%

69%

-2%

68%

62%

6%

EBITDA

16.08

13.21

22%

30.63

25.44

20%

EBITDA%

22%

20%

2%

21%

17%

4%

PAT  

9.34

6.78

38%

17.77

13.25

34%

PAT%

13%

10%

3%

12%

9%

3%

EPS (In ₹, not annualized)

10.97

7.97

38%

20.89

15.58

34%

 

  1. Although the gross profit margin remained stable in Q2 FY25 due to the product mix, it saw a 6% increase in H1 FY25, driven by a more optimal product mix.
  2. Higher revenue from divisional product sales led to better absorption of fixed costs, improving the EBITDA margin by 2%.
  3. Absolute PAT rose by 38%, aligning with sales growth, and the PAT% increased by 3%, highlighting enhanced operational efficiency.

 

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024